Positive results of treatment of adenocystic carcinoma of the parotid salivary gland with lenvatinib
https://doi.org/10.17650/2222-1468-2024-14-3-10-13
Abstract
Malignant tumors of the salivary glands account for 3–5 % of all head and neck cancers. Adenocystic carcinomas are malignant neoplasms that most often arise from large and small salivary glands. The disease is characterized by a progressive course with local and distant relapses.
The article presents a clinical case of successful treatment with lenvatinib in suboptimal doses of adenocystic carcinoma of the parotid salivary gland.
About the Authors
I. A. Filippov
Multidisciplinary Medical Clinical Center “Medical City”
Russian Federation
Russian Federation
32 Barnaulskaya St., Tyumen 625041
M. S. Shvedsky
Tyumen State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
54 Odesskaya St., Tyumen 625023
E. A. Gaisina
Multidisciplinary Medical Clinical Center “Medical City”; Tyumen State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
32 Barnaulskaya St., Tyumen 625041
54 Odesskaya St., Tyumen 625023
L. A. Bakhova
Multidisciplinary Medical Clinical Center “Medical City”; Tyumen State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
32 Barnaulskaya St., Tyumen 625041
54 Odesskaya St., Tyumen 625023
References
1. Boyle T.A.C., Laurent S., Semus S., Joseph N. Epidemiology of adenoid cystic carcinoma in the United States. JCO 2020;38(15):e13600. DOI: 10.1200/JCO.2020.38.15_suppl.e13600
2. Fang Y., Peng Z., Wang Y. et al. Current opinions on diagnosis and treatment of adenoid cystic carcinoma. Oral Oncol 2022;130:105945. DOI: 10.1016/j.oraloncology.2022.105945
3. Su M., Zhang Z., Zhou L. et al. Proteomics, personalized medicine and cancer. Cancers 2021;13(11):2512. DOI: 10.3390/cancers13112512
4. Alfieri S., Granata R., Bergamini C. et al. Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm? Oral Oncol 2017;66:58–63. DOI: 10.1016/j.oraloncology.2016.12.016
5. Ferrarotto R., Wirth L.J., Muzaffar J. et al. 919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut). Ann Oncol 2020;31(4):S663. DOI: 10.1016/j.annonc.2020.08.1034
6. Yamamoto Y., Matsui J., Matsushima T. et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 2014;6:18. DOI: 10.1186/2045-824X-6-18
7. Chau N.G., Hotte S.J., Chen E.X. et al. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol 2012;23(6):1562–70. DOI: 10.1093/annonc/mdr522
8. Dillon P.M., Petroni G.R., Horton B.J. et al. A Phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma. Clin Cancer Res 2017;23(15):4138–45. DOI: 10.1158/1078-0432.CCR-16-2942
9. Thomson D.J., Silva P., Denton K. et al. Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Head Neck 2015;37(2):182–7. DOI: 10.1002/hed.23577
10. Wong S.J., Karrison T., Hayes D.N. et al. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol 2016;27(2):318–23. DOI: 10.1093/annonc/mdv537
11. Tchekmedyian V., Sherman E.J., Dunn L. et al. Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. JCO 2019;37(18):1529–37. DOI: 10.1200/JCO.18.01859
12. Mohamadpour M., Sherman E.J., Kriplani A. et al. A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma. JCO 2023;41(16):6048. DOI: 10.1200/JCO.2023.41.16_suppl.6048
Review
For citations:
Filippov I.A., Shvedsky M.S., Gaisina E.A., Bakhova L.A. Positive results of treatment of adenocystic carcinoma of the parotid salivary gland with lenvatinib. Head and Neck Tumors (HNT). 2024;14(3):10-13. (In Russ.) https://doi.org/10.17650/2222-1468-2024-14-3-10-13
Views:
288
Email this article 